Drug design, development and therapy 9:24852499 Cooke JP, Losordo DW (2015) Modulating the vascular response to limb ischemia: angiogenic and cell therapies
The combination of GPX4 inhibitors with immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 axis increases the proportion of CD8 + T cells, enhances their cytotoxic activity and induces ferroptosis, thereby promoting chemotherapy resistance [42]
That's a meaningfully different claim than what most product pages make
This puts you near the middle of your dosing cycle, when tirzepatide levels are steady and not at their peak or trough
"It was particularly encouraging to see these results consistently demonstrated across the REIMAGINE trials in adults with type 2 diabetes at various stages of their disease, from first-line therapy to add-on to basal insulin
For patients at moderate risk of rhabdomyolysis who are at low risk of fluid overload, consider empiric IV fluid administration (e.g., D5LR at 150 ml/hr)